



Tyzeka® (telbivudine) – Product Discontinuation

- On September 30, 2016, the [FDA announced](#) the discontinuation of Novartis' [Tyzeka \(telbivudine\)](#) 600 mg tablets.
 - The discontinuation is not due to manufacturing, product quality, safety, or efficacy concerns.
 - Generic equivalents are not available; however, other therapeutic alternatives are available. Patients should speak to their healthcare provider regarding their hepatitis B therapy.
- Tyzeka is indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- For additional questions, contact Novartis at **1-888-669-6682**.

Action Plan

- Information regarding Tyzeka will be posted on the [optumrx.com](#) portals.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.